Bevacizumab in Combination With Chemotherapy: First-Line Treatment of Patients With Metastatic Colorectal Cancer
- 31 October 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 33, S8-S14
- https://doi.org/10.1053/j.seminoncol.2006.08.005
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2006
- Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC)Journal of Clinical Oncology, 2005
- Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II TrialJournal of Clinical Oncology, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroupsJournal of Clinical Oncology, 2004
- Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)Journal of Clinical Oncology, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinomaEuropean Journal of Surgical Oncology, 2000